SCHEMBL2200573

SCHEMBL2200573

COc1cc(C=C2SC(=S)NC2=O)ccc1OCc1ccc(C(F)(F)F)cc1C(F)(F)F

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CISD1 Q9NZ45 3/20 0.65
PDE4B Q07343 5/20 0.64
PDE3A Q14432 4/20 0.64
MEN1 O00255 2/20 0.64
KMT2A Q03164 2/20 0.64
ALDH1A1 P00352 1/20 0.64
LMNA P02545 1/20 0.64
MAPT P10636 1/20 0.64
NPSR1 Q6W5P4 1/20 0.64
ADAMTS5 Q9UNA0 3/20 0.64
ESRRA P11474 3/20 0.64
FOXM1 Q08050 1/20 0.61
DYRK1A Q13627 1/20 0.59
MGAM O43451 1/20 0.56
GAA P10253 1/20 0.56
SI P14410 1/20 0.56
MGAM2 Q2M2H8 1/20 0.56
CYP3A4 P08684 1/20 0.55
MAOA P21397 1/20 0.54
MAOB P27338 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2697203 0.92 ESRRA (0.75) PDE4BMEN1KMT2AESRRAFOXM1
SCHEMBL2697205 0.92 ESRRA (0.75) PDE4BMEN1KMT2AESRRAFOXM1
SCHEMBL23496327 0.88 ADAMTS5 (0.79) CISD1PDE4BPDE3AMEN1KMT2A
SCHEMBL23496326 0.88 ADAMTS5 (0.79) CISD1PDE4BPDE3AMEN1KMT2A
SCHEMBL2697148 0.87 ESRRA (0.64) PDE4BMEN1KMT2AALDH1A1LMNA
SCHEMBL2697151 0.87 ESRRA (0.64) PDE4BMEN1KMT2AALDH1A1LMNA
SCHEMBL2201951 0.86 FOXM1 (0.64) CISD1MEN1KMT2AADAMTS5ESRRA
SCHEMBL23496315 0.85 CISD1 (0.76) CISD1PDE4BPDE3AMEN1KMT2A
SCHEMBL23496313 0.85 CISD1 (0.76) CISD1PDE4BPDE3AMEN1KMT2A
SCHEMBL5613820 0.84 CA2 (0.61) CISD1PDE4BPDE3AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977489-B2 Benzylthiazolone inhibitors of estrogen-related receptors (ERR) EXELIXIS, INC. (US) 2011-07-12 US disclosed
US-7977489-B2 Benzylthiazolone inhibitors of estrogen-related receptors (ERR) EXELIXIS, INC. (US) 2011-07-12 US disclosed
US-20090197870-A1 Pharmaceutical Compositions EXELIXIS, INC. (US) 2009-08-06 US disclosed
US-20090197870-A1 Pharmaceutical Compositions EXELIXIS, INC. (US) 2009-08-06 US disclosed
EP-1805154-A2 PHARMACEUTICAL COMPOSITIONS Exelixis, Inc. (US) 2007-07-11 EP disclosed
WO-2006047269-A2 PHARMACEUTICAL COMPOSITIONS EXELIXIS, INC. (US) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197870-A1 Pharmaceutical Compositions ESRRA, ESRRB, ESR2 CISD1 4710/4885PDE4B 721/4885PDE3A 661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.